GOLDMAN SACHS GROUP INC - JOUNCE THERAPEUTICS INC ownership

JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 125 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 6.50 and the average weighting 0.4%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of JOUNCE THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$79,405
-43.6%
42,922
-66.1%
0.00%
Q4 2022$140,688
-62.8%
126,746
-21.5%
0.00%
Q3 2022$378,000
-39.0%
161,519
-21.1%
0.00%
Q2 2022$620,000
-76.7%
204,633
-47.8%
0.00%
-100.0%
Q1 2022$2,661,000
-55.8%
391,916
-45.6%
0.00%0.0%
Q4 2021$6,016,000
+20.2%
720,445
+6.9%
0.00%0.0%
Q3 2021$5,007,000
+347.9%
673,926
+310.1%
0.00%
Q2 2021$1,118,000
-28.1%
164,349
+8.6%
0.00%
Q1 2021$1,554,000
+524.1%
151,311
+325.7%
0.00%
Q4 2020$249,000
-19.7%
35,547
-6.7%
0.00%
Q3 2020$310,000
-20.9%
38,087
-33.0%
0.00%
Q2 2020$392,000
+3.2%
56,872
-28.9%
0.00%
Q1 2020$380,000
-60.8%
79,962
-27.9%
0.00%
Q4 2019$969,000
+112.5%
110,966
-18.9%
0.00%
Q3 2019$456,000
-1.7%
136,789
+46.0%
0.00%
Q2 2019$464,000
-17.1%
93,675
+3.7%
0.00%
Q1 2019$560,000
+74.5%
90,301
-5.2%
0.00%
Q4 2018$321,000
-51.4%
95,222
-6.4%
0.00%
Q3 2018$661,000
+2.8%
101,738
+21.1%
0.00%
Q2 2018$643,000
-62.5%
83,996
+9.4%
0.00%
Q1 2018$1,716,000
+117.8%
76,780
+24.3%
0.00%
Q4 2017$788,000
-56.0%
61,787
-46.3%
0.00%
Q3 2017$1,791,000
+83.3%
114,962
+65.1%
0.00%
Q2 2017$977,000
+260.5%
69,648
+465.7%
0.00%
Q1 2017$271,00012,3120.00%
Other shareholders
JOUNCE THERAPEUTICS INC shareholders Q1 2021
NameSharesValueWeighting ↓
TRV GP II, LLC 1,347,829$9,152,00093.42%
Ally Bridge Group (NY) LLC 550,000$3,735,0002.77%
ACUTA CAPITAL PARTNERS, LLC 813,500$5,524,0002.58%
TRV GP III, LLC 1,148,780$7,800,0002.12%
Deep Track Capital, LP 4,259,653$28,923,0001.86%
Logos Global Management LP 1,400,000$9,506,0001.23%
PFM Health Sciences, LP 3,972,868$26,976,0001.01%
Sofinnova Investments, Inc. 1,481,219$10,057,0000.76%
SILVERARC CAPITAL MANAGEMENT, LLC 248,347$1,686,0000.70%
RTW INVESTMENTS, LP 4,680,412$31,780,0000.66%
View complete list of JOUNCE THERAPEUTICS INC shareholders